NICE technology appraisal guidance
Issued: September 2009
TA180
Ustekinumab for the treatment of adults with moderate to severe psoriasis
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta180
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp